HylNeuro™ — Precision HA-Conjugate Delivery Across the Blood-Brain Barrier
HylNeuro™ is our proprietary hyaluronan-based conjugate platform designed to deliver therapeutics precisely into the central nervous system (CNS) across the blood-brain barrier (BBB). It enhances uptake and sustained retention of hyaluronan-drug conjugates that are poorly brain-penetrant or limited by systemic exposure constraints.
HylNeuro™ platform is specifically optimized for small molecules, peptides, or hormonal agents struggle to achieve targeted CNS delivery without peripheral toxicity. Tailor-made HA polymers, fine-tuned for molecular weight and designed linkers, allow conjugation with therapeutics requiring brain-selective restoration and stability.
Preclinical validation with ND108E, a HylNeuro™-based conjugate, demonstrated robust brain targeting, cognitive recovery, and minimal systemic exposure in Alzheimer's disease animal models. This highlights HylNeuro™'s unique capability to selectively restore neural circuits in neurodegenerative disease.
HylNeuro™ represents a new paradigm in CNS drug delivery — enabling site-specific, sustained exposure without chronic systemic burden — opening collaboration opportunities for innovative CNS therapeutics
前のページ